DE50009240D1 - Verwendung von Antikörpern zur Vakzinierung gegen Krebs - Google Patents

Verwendung von Antikörpern zur Vakzinierung gegen Krebs

Info

Publication number
DE50009240D1
DE50009240D1 DE50009240T DE50009240T DE50009240D1 DE 50009240 D1 DE50009240 D1 DE 50009240D1 DE 50009240 T DE50009240 T DE 50009240T DE 50009240 T DE50009240 T DE 50009240T DE 50009240 D1 DE50009240 D1 DE 50009240D1
Authority
DE
Germany
Prior art keywords
against cancer
antibodies
vaccinate against
vaccinate
prophylactically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE50009240T
Other languages
German (de)
English (en)
Inventor
Helmut Eckert
Hans Loibner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-GmbH
Original Assignee
Igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-GmbH filed Critical Igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-GmbH
Application granted granted Critical
Publication of DE50009240D1 publication Critical patent/DE50009240D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE50009240T 1999-01-13 2000-01-12 Verwendung von Antikörpern zur Vakzinierung gegen Krebs Expired - Lifetime DE50009240D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH5199 1999-01-13

Publications (1)

Publication Number Publication Date
DE50009240D1 true DE50009240D1 (de) 2005-02-17

Family

ID=4178206

Family Applications (2)

Application Number Title Priority Date Filing Date
DE50009240T Expired - Lifetime DE50009240D1 (de) 1999-01-13 2000-01-12 Verwendung von Antikörpern zur Vakzinierung gegen Krebs
DE50000243T Expired - Lifetime DE50000243D1 (de) 1999-01-13 2000-01-12 Verwendung von antikörpern zur vakzinierung gegen krebs

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE50000243T Expired - Lifetime DE50000243D1 (de) 1999-01-13 2000-01-12 Verwendung von antikörpern zur vakzinierung gegen krebs

Country Status (28)

Country Link
US (3) US7691372B2 (enExample)
EP (2) EP1140168B1 (enExample)
JP (1) JP4774551B2 (enExample)
KR (1) KR100771752B1 (enExample)
CN (1) CN1188169C (enExample)
AT (2) ATE219687T1 (enExample)
AU (1) AU768515B2 (enExample)
CA (1) CA2360382C (enExample)
CZ (1) CZ302801B6 (enExample)
DE (2) DE50009240D1 (enExample)
DK (2) DK1140168T3 (enExample)
EE (1) EE05474B1 (enExample)
ES (2) ES2236375T3 (enExample)
HK (1) HK1044487B (enExample)
HR (1) HRP20010526A2 (enExample)
HU (1) HU226150B1 (enExample)
ID (1) ID30223A (enExample)
IL (2) IL144265A0 (enExample)
IS (1) IS5998A (enExample)
MX (1) MXPA01007148A (enExample)
NO (1) NO329917B1 (enExample)
NZ (1) NZ512722A (enExample)
PL (1) PL201533B1 (enExample)
PT (2) PT1230932E (enExample)
SI (2) SI1140168T1 (enExample)
SK (1) SK286627B6 (enExample)
TR (1) TR200102034T2 (enExample)
WO (1) WO2000041722A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1230932E (pt) * 1999-01-13 2005-04-29 Igeneon Krebs Immuntherapie Uso de anticorpos para vacinacao contra o cancro
AT410172B (de) * 2000-03-21 2003-02-25 Igeneon Gmbh Verfahren zur herstellung einer vakzineformulierung
AT502293B1 (de) * 2002-05-15 2008-03-15 Igeneon Krebs Immuntherapie Immunogener, monoklonaler antikörper
AT500647A1 (de) * 2002-05-21 2006-02-15 Igeneon Krebs Immuntherapie Verwendung eines impfstoffes
AT500650B1 (de) * 2003-04-17 2009-11-15 Altropus Gmbh Immunogener rekombinanter antikörper
AT500651B9 (de) * 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
JP2008505943A (ja) 2004-07-14 2008-02-28 イゲネーオン・クレープス−イムンテラピー・フォルシュングス−ウント・エントヴィックルングス−アクチェンゲゼルシャフト グリコシル化抗体
ATE483473T1 (de) * 2004-07-20 2010-10-15 Altropus Gmbh Verwendung von antikörpern in einer sehr geringen dosis zur impfung gegen krebs
CN101355928B (zh) * 2005-04-26 2013-05-22 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和方法
CA2652434A1 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized proteins that target ep-cam
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
AT504231A1 (de) 2006-10-03 2008-04-15 Hans Dr Loibner Prädiktive parameter
BRPI0821165B8 (pt) 2007-12-07 2021-05-25 Nutricia Nv uso de uma composição
CA2744103C (en) 2009-02-24 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Methods for identifying immunobinders of cell-surface antigens
US8887373B2 (en) 2012-02-24 2014-11-18 Covidien Lp Vessel sealing instrument with reduced thermal spread and method of manufacture therefor
US20140276968A1 (en) * 2013-03-14 2014-09-18 Ethicon, Inc. Applicator systems for surgical fasteners
US10196458B2 (en) * 2013-07-26 2019-02-05 The Regents Of The University Of California Anti-immunoglobulin E antibodies and methods of using thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341281C (en) * 1986-07-09 2001-08-07 Hubert J.P. Schoemaker Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen
US5270202A (en) * 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5798100A (en) * 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
WO1997005597A1 (en) * 1995-07-31 1997-02-13 Litton Systems Canada Limited Flat panel pixel array incorporating photoconductive switches
WO1997015597A1 (en) * 1995-10-25 1997-05-01 Centocor B.V. HUMAN EPITHELIAL ANTIGEN Ep-CAM DERIVED PEPTIDES AND THEIR USE
US6235280B1 (en) * 1996-04-12 2001-05-22 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
IL121041A0 (en) * 1997-06-09 1997-11-20 Yeda Res & Dev Immunogenic compositions for induction of anti-tumor immunity
US6274143B1 (en) * 1997-06-13 2001-08-14 Malaya Chatterjee Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
WO1999065523A1 (en) * 1998-06-15 1999-12-23 Altarex Corp. Immunotherapeutic composition and method for the treatment of prostate cancer
PT1230932E (pt) * 1999-01-13 2005-04-29 Igeneon Krebs Immuntherapie Uso de anticorpos para vacinacao contra o cancro
WO2001087233A2 (en) * 2000-05-16 2001-11-22 New York University Anti-idiotypic antibody against fimh adhesin of uropathogenic type i-fimbriated escherichia coli, compositions and method of use thereof

Also Published As

Publication number Publication date
EE200100366A (et) 2002-10-15
HU226150B1 (en) 2008-05-28
US20070224202A1 (en) 2007-09-27
US8444974B2 (en) 2013-05-21
ATE286745T1 (de) 2005-01-15
JP2002534481A (ja) 2002-10-15
HUP0200527A2 (en) 2002-06-29
IL144265A0 (en) 2002-05-23
HK1044487B (zh) 2005-09-16
CA2360382A1 (en) 2000-07-20
AU2796400A (en) 2000-08-01
NO329917B1 (no) 2011-01-24
CA2360382C (en) 2011-05-24
ATE219687T1 (de) 2002-07-15
US7691372B2 (en) 2010-04-06
ES2236375T3 (es) 2005-07-16
CZ302801B6 (cs) 2011-11-16
US20100233178A1 (en) 2010-09-16
IS5998A (is) 2001-07-10
DE50000243D1 (de) 2002-08-01
ES2177509T3 (es) 2002-12-16
NZ512722A (en) 2003-07-25
EP1140168A1 (de) 2001-10-10
SI1230932T1 (en) 2005-06-30
PL364747A1 (en) 2004-12-13
CN1188169C (zh) 2005-02-09
EP1230932B1 (de) 2005-01-12
MXPA01007148A (es) 2002-03-27
KR100771752B1 (ko) 2007-10-30
US20120003232A1 (en) 2012-01-05
DK1230932T3 (da) 2005-04-25
SI1140168T1 (en) 2002-10-31
JP4774551B2 (ja) 2011-09-14
PT1140168E (pt) 2002-11-29
KR20010101446A (ko) 2001-11-14
HK1044487A1 (en) 2002-10-25
EP1230932A2 (de) 2002-08-14
EP1230932A3 (de) 2003-11-26
CN1344167A (zh) 2002-04-10
IL144265A (en) 2006-08-20
TR200102034T2 (tr) 2001-11-21
AU768515B2 (en) 2003-12-18
EE05474B1 (et) 2011-10-17
DK1140168T3 (da) 2002-09-30
NO20013093D0 (no) 2001-06-21
SK286627B6 (sk) 2009-02-05
PT1230932E (pt) 2005-04-29
PL201533B1 (pl) 2009-04-30
HRP20010526A2 (en) 2002-08-31
ID30223A (id) 2001-11-15
EP1140168B1 (de) 2002-06-26
WO2000041722A1 (de) 2000-07-20
SK9642001A3 (en) 2002-03-05
CZ20012581A3 (cs) 2002-01-16
NO20013093L (no) 2001-09-10

Similar Documents

Publication Publication Date Title
DE50009240D1 (de) Verwendung von Antikörpern zur Vakzinierung gegen Krebs
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
CR8698A (es) Anticuerpos monoclonales al factor de crecimiento de hepatocito
TR200001253T2 (tr) Tümöre özel antijenler
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
TR200602095T2 (tr) Hümanize Anti-LT-Beta-R antikorları
MXPA05009751A (es) Anticuerpo monoclonal e hibridoma que lo produce.
ATE403680T1 (de) Herstellung tetravalenter antikörper
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
CY1108020T1 (el) Μονοκλωνικα αντισωματα στον ανθρωπινο υποδοχεα ldl, η παραγωγη και χρηση τους
ATE366746T1 (de) Gegen das semp1-protein gerichtete antikörper, verfahren zu deren herstellung, und deren anwendungen
DE50111331D1 (de) Neue verwendung von proteinhydrolysaten
ATE171473T1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
ATE490271T1 (de) Rezeptor, dessen verwendung sowie mausantikörper
ATE483473T1 (de) Verwendung von antikörpern in einer sehr geringen dosis zur impfung gegen krebs
CY1114280T1 (el) Αντισωματα ανταγωνιστων των κυτοκινων θηλαστικων ή οι υποδοχεις τους για την αγωγη της αλλεργιας
CY1117275T1 (el) Μεθοδοι θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος enanti-erbb-μεϊτανσινοειδους
ATE297745T1 (de) Chemische modifizierung von harn von säugern
BR0007814A (pt) Uso de anticorpos para a vacinação contra câncer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition